Therapeutic Drug Levels
Table 1. Therapeutic Drug Levels [1, 2, 3, 4] (Open Table in a new window)
Drug |
Therapeutic Range |
10-25 μg/mL |
|
Nonbacteremic gram-negative infection (urinary tract infection, synergism with beta-lactams): 15-30 μg/mL Serious gram-negative infection (bacteremia, pneumonia, sepsis): 25-40 μg/mL |
|
120-150 ng/mL |
|
4-12 μg/mL |
|
Meningitis: 15-25 μg/mL Other infections: 10-20 μg/mL |
|
100-300 ng/mL |
|
0.8-2 ng/mL |
|
2-4 μg/mL |
|
40-100 μg/mL |
|
Adults: 0.2-1 μg/mL Children: 0.2-0.8 μg/mL |
|
5-10 μg/mL |
|
150-250 ng/mL |
|
15-30 μg/mL |
|
1.5-5 μg/mL |
|
Relapse prevention for bipolar disorder: 0.6-1 mEq/L Acute mania: 0.8-1.2 mEq/L Elderly patients: 0.4-0.8 mEq/L |
|
High-dose regimens result in 0.1-1 μmol/L 24-72 h postinfusion Toxic levels: >0.2 μmol/L (low-dose); >1 μmol/L (high-dose) |
|
50-150 ng/mL |
|
Adults: 10-40 μg/mL Infants/children: 15-30 μg/mL |
|
Total phenytoin levels: 10-20 μg/mL |
|
5-12 μg/mL |
|
Procainamide: 4-8 μg/mL N-acetylprocainamide: 4-8 μg/mL |
|
2-5 μg/mL |
|
Salicylate |
Antiplatelet/analgesia/antipyretic: ~100 μg/mL Mild toxic effects observed with anti-inflammatory dose levels of 150-300 μg/mL |
5-15 μg/L (whole blood) |
|
5-20 μg/L (whole blood) |
|
Adults: 5-15 μg/mL Children: 5-10 μg/mL Neonatal apnea: 6-11 μg/mL |
|
Life-threatening infection: 8-10 μg/mL Serious infection: 6-8 μg/mL Urinary tract infection: 4-6 μg/mL Synergy for infections caused by gram-positive organisms: 3-5 μg/mL |
|
Epilepsy (total): 50-100 μg/mL Mania (total): 50-125 μg/mL Free: 6-22 μg/mL |
|
50-125 microgram/L (serum or plasma) 150-400microgram/L (whole blood) |
Tables
Drug |
Therapeutic Range |
10-25 μg/mL |
|
Nonbacteremic gram-negative infection (urinary tract infection, synergism with beta-lactams): 15-30 μg/mL Serious gram-negative infection (bacteremia, pneumonia, sepsis): 25-40 μg/mL |
|
120-150 ng/mL |
|
4-12 μg/mL |
|
Meningitis: 15-25 μg/mL Other infections: 10-20 μg/mL |
|
100-300 ng/mL |
|
0.8-2 ng/mL |
|
2-4 μg/mL |
|
40-100 μg/mL |
|
Adults: 0.2-1 μg/mL Children: 0.2-0.8 μg/mL |
|
5-10 μg/mL |
|
150-250 ng/mL |
|
15-30 μg/mL |
|
1.5-5 μg/mL |
|
Relapse prevention for bipolar disorder: 0.6-1 mEq/L Acute mania: 0.8-1.2 mEq/L Elderly patients: 0.4-0.8 mEq/L |
|
High-dose regimens result in 0.1-1 μmol/L 24-72 h postinfusion Toxic levels: >0.2 μmol/L (low-dose); >1 μmol/L (high-dose) |
|
50-150 ng/mL |
|
Adults: 10-40 μg/mL Infants/children: 15-30 μg/mL |
|
Total phenytoin levels: 10-20 μg/mL |
|
5-12 μg/mL |
|
Procainamide: 4-8 μg/mL N-acetylprocainamide: 4-8 μg/mL |
|
2-5 μg/mL |
|
Salicylate |
Antiplatelet/analgesia/antipyretic: ~100 μg/mL Mild toxic effects observed with anti-inflammatory dose levels of 150-300 μg/mL |
5-15 μg/L (whole blood) |
|
5-20 μg/L (whole blood) |
|
Adults: 5-15 μg/mL Children: 5-10 μg/mL Neonatal apnea: 6-11 μg/mL |
|
Life-threatening infection: 8-10 μg/mL Serious infection: 6-8 μg/mL Urinary tract infection: 4-6 μg/mL Synergy for infections caused by gram-positive organisms: 3-5 μg/mL |
|
Epilepsy (total): 50-100 μg/mL Mania (total): 50-125 μg/mL Free: 6-22 μg/mL |
|
50-125 microgram/L (serum or plasma) 150-400microgram/L (whole blood) |
